Diagnostic Products

At Epigenomics we develop and commercialize innovative molecular diagnostic tests that address unmet needs in cancer screening, diagnosis and patient management.

Our product portfolio includes Epi proColon®, a blood-based test for the detection of colorectal cancer and Epi proLung®, a confirmatory test that aids in the diagnosis of lung cancer. Epi proLung is not available in the United States.

Our development pipeline also contains tests for screening, monitoring, diagnosis and prognosis assessment in colorectal and lung cancer.